

Poster presentation

Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable

Apostolos Aidonopoulos^{*1}, Anastasios Kanistras¹, Anastasia Karastergiou¹, Athanasios Karavatos², Konstantinos Katsafouros³, Konstantinos Kontis⁴, Venetsanos Mavreas⁵, Maria Tzanakaki⁶, Nikolaos Tzavaras⁷ and Errikos Tzebelikos⁸

Address: ¹Psychiatric Hospital of Thessaloniki, Greece, ²1st Department Of Psychiatry, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Greece, ³Psychiatric Hospital of Athens "Dromokaition", Greece, ⁴Psychiatric Hospital of Athens "Dafni", Greece, ⁵University Hospital of Ioannina, Greece, ⁶Chania Hospital for Mental Illnesses, Greece, ⁷Alexandroupoli General Hospital, Greece and ⁸Sismanogliou General Hospital, Greece

* Corresponding author

from International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour Thessaloniki, Greece. 17–20 November 2005

Published: 28 February 2006

Annals of General Psychiatry 2006, **5**(Suppl 1):S302 doi:10.1186/1744-859X-5-S1-S302

Background

Risperidone microspheres represents the first long-acting injectable preparation of an atypical antipsychotic. The Switch to Risperidone Microspheres (StoRMI) trial investigated the maintained efficacy and safety of this formulation of risperidone long-acting microspheres in patients with schizophrenia or other psychotic disorders when switching from typical depot or oral neuroleptics to long-acting risperidone microspheres. We report here the results of a subgroup analysis of Greek patients.

Materials and methods

Patients who were symptomatically stable on any previous antipsychotic medication for ≥ 1 month received intramuscular injections of long-acting risperidone 25 mg (increased to 37.5 or 50 mg, if necessary) every two weeks for 6 months. Previous antipsychotics were continued concomitantly during the first 3 weeks of long-acting risperidone therapy.

Results

The analysis included 91 male and 31 female patients of mean age 42.5 years. The majority of patients had schizophrenia (84%; mostly paranoid according to DSM-IV criteria). Other diagnoses were schizoaffective disorder (9%) and other psychotic disorders (8%). Previous antipsychotic therapy was mostly atypical antipsychotics (72%) as well as conventional depot and oral antipsychotics. Reasons for switching were mainly (66%) non-compliance

with previous therapy (66%), insufficient efficacy (22%) and side effects (18%). The majority of patients (77%) completed the 6-months period of therapy; most common reasons for discontinuation were adverse events (9%), withdrawal of consent (8%), and patients lost to follow-up (6%). There were significant reductions from baseline ($p < 0.001$) at 1, 3, and 6 months in mean scores for the total PANSS as well as for positive, negative and general psychopathology subscales. At endpoint, 73% of patients had $>20\%$ improvement in PANSS total scores. According to the Clinical Global Impression (CGI), patients improved significantly ($p < 0.001$) with the group classified as "not ill/borderline ill" rising from 2.5% at baseline to 16% at endpoint. There were significant improvements from baseline to endpoint ($p < 0.0001$) in all components of SF-36 Quality of Life Questionnaire. Global Assessment of Function (GAF) and patient satisfaction also increased significantly ($p < 0.0001$) from baseline. No unexpected adverse events were reported and the ESRS total scores of ESRS were reduced significantly ($p < 0.005$) from baseline at all visits.

Discussion

Switching to long-acting injectable risperidone was associated with significant improvement of symptoms. Efficacy was not only maintained but patients showed further, significant, sustained improvement of symptoms after switching. Patient satisfaction was significantly higher at endpoint than at baseline.

Acknowledgements

This study was supported by Janssen-Cilag

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

